- RNAi therapeutics, offering targeted gene-silencing mechanisms, are increasingly vital components of modern precision medicine, particularly in treating genetic disorders, cancers, and rare diseases. Their ability to specifically inhibit the expression of disease-causing genes is revolutionizing treatment approaches across both clinical and research settings.
- The escalating demand for RNA Interference (RNAi) nucleic acid therapeutics is primarily fueled by the growing prevalence of chronic and genetic diseases, advancements in oligonucleotide delivery systems, and strong pipeline developments by leading pharmaceutical companies. In Addition, favorable regulatory support and rising R&D investment are contributing to accelerating the commercialization of RNAi-based therapies
- North America dominated the RNA Interference (RNAi) Nucleic Acid Therapeutics market with the largest revenue share of 45.7% in 2024, driven by robust healthcare infrastructure, early adoption of advanced therapeutics, high healthcare expenditure, and strong presence of key industry players such as Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals
- Asia-Pacific is expected to be the fastest-growing region in the RNA Interference (RNAi) Nucleic Acid Therapeutics market during the forecast period, with a projected CAGR of 17.4%, attributed to improving healthcare systems, growing investments in biotechnology, and increasing collaborations between regional pharmaceutical firms and global RNAi drug developers
- The Small Interfering RNA (siRNA) segment dominated the RNA Interference (RNAi) Nucleic Acid Therapeutics market with a market share of 61.3% in 2024, owing to its proven clinical efficacy, well-established delivery systems, and higher number of FDA-approved therapies. siRNA-based drugs such as Onpattro and Givlaari have paved the way for expanding RNAi drug pipelines globally
